{"organizations": [], "uuid": "88d746d39bdb81d19ecbdebba1abb09cb96f102b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ani-pharmaceuticals-to-acquire-gen/brief-ani-pharmaceuticals-to-acquire-generic-products-and-assets-from-amneal-impax-idUSASC09Y4D", "country": "US", "domain_rank": 408, "title": "BRIEF-Ani Pharmaceuticals To Acquire Generic Products And Assets From Amneal/Impax", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-28T01:38:00.000+03:00", "replies_count": 0, "uuid": "88d746d39bdb81d19ecbdebba1abb09cb96f102b"}, "author": "", "url": "https://www.reuters.com/article/brief-ani-pharmaceuticals-to-acquire-gen/brief-ani-pharmaceuticals-to-acquire-generic-products-and-assets-from-amneal-impax-idUSASC09Y4D", "ord_in_thread": 0, "title": "BRIEF-Ani Pharmaceuticals To Acquire Generic Products And Assets From Amneal/Impax", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "impax", "sentiment": "none"}, {"name": "amneal/impax ani pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 27 (Reuters) - ANI Pharmaceuticals Inc:\n* ANI PHARMACEUTICALS SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE GENERIC PRODUCTS AND ASSETS FROM AMNEAL/IMPAX\n* ANI PHARMACEUTICALS INC - TRANSACTION IS RESULT OF A DIVESTITURE PROCESS MANDATED BY FEDERAL TRADE COMMISSION\n* ANI PHARMACEUTICALS - TO BUY PORTFOLIO OF GENERIC PRODUCTS FROM AMNEAL PHARMACEUTICALS AND IMPAX LABORATORIES () FOR UNDISCLOSED CASH CONSIDERATION\n* ANI PHARMACEUTICALS - DEAL IS RESULT OF DIVESTITURE PROCESS MANDATED IN CONNECTION WITH AMNEAL PHARMACEUTICALâ€™S PROPOSED DEAL WITH IMPAX LABORATORIES\n* ANI PHARMACEUTICALS - CO WILL SECURE SUPPLY AGREEMENT WITH OPTION TO RECEIVE GENERIC ASPIRIN/DIPYRIDAMOLE ER CAPSULES FROM AMNEAL BEGINNING IN LATE 2019\n* ANI PHARMACEUTICALS - UPON DEAL CLOSING , ANI TO BUY PRODUCT PORTFOLIO CONSISTING OF 5 APPROVED GENERIC ANDAS, 1 PIPELINE PRODUCT, ERYTHROMYCIN IR TABLETS\n* ANI PHARMACEUTICALS INC - ANI WILL ACQUIRE LICENSE, SUPPLY & DISTRIBUTION AGREEMENT FOR A SECOND PIPELINE PRODUCT, DICLOFENAC-MISOPROSTOL DR TABLETS Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-28T01:38:00.000+03:00", "crawled": "2018-04-28T01:57:16.011+03:00", "highlightTitle": ""}